Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Amortization of Deferred Charges (2019 - 2021)

UroGen Pharma (URGN) has disclosed Amortization of Deferred Charges for 3 consecutive years, with $232000.0 as the latest value for Q2 2021.

  • For the quarter ending Q2 2021, Amortization of Deferred Charges fell 38.79% year-over-year to $232000.0, compared with a TTM value of $1.3 million through Jun 2021, up 4.19%, and an annual FY2020 reading of $1.6 million, up 58.37% over the prior year.
  • Amortization of Deferred Charges was $232000.0 for Q2 2021 at UroGen Pharma, down from $237000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $494000.0 in Q4 2020 and bottomed at $232000.0 in Q2 2021.
  • Average Amortization of Deferred Charges over 3 years is $312500.0, with a median of $269000.0 recorded in 2019.
  • The sharpest move saw Amortization of Deferred Charges soared 69.18% in 2020, then crashed 38.79% in 2021.
  • Year by year, Amortization of Deferred Charges stood at $292000.0 in 2019, then skyrocketed by 69.18% to $494000.0 in 2020, then crashed by 53.04% to $232000.0 in 2021.
  • Business Quant data shows Amortization of Deferred Charges for URGN at $232000.0 in Q2 2021, $237000.0 in Q1 2021, and $494000.0 in Q4 2020.